ProfessorDirector of Innovation and Commercialization, Director of Entrepreneurship Education, SPARK/REACH Program, Director of the Center of Excellence Program for Model Informed Drug Development
BS Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania (Magna Cum Laude)
Awards
Affiliations
Professor, University of Colorado, School of Medicine, Division of Kidney Diseases and Hypertension
Member, University of Colorado, Cancer Center
Member, Colorado Center for Personalized Medicine
Member, Center for Translational Pharmacokinetics and Pharmacogenomics
Member, Center for Drug Discovery
Member, Colorado Center for Nanomedicine and Nanosafety
Founder/Scientific Advisor, Katharos, Inc.
Research Interest
Kidney Disease Pharmacology
Publications and Presentations
Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant CL, Bowles DW, George B, Wen X, Buckley B, Aleksunes L, Joy MS. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Eur J Clin Pharmacol. 2018 Sep 15. [Epub ahead of print]. PMID: 30220072.
Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O’Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Pharmacogenomic variants may influence the urinary excretion of novel kidney injury biomarkers in patients receiving cisplatin. Int J Mol Sci 2017;Jun 22;18(7).
Skaggs School of Pharmacy and Pharmaceutical Sciences